Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EX3617 / 1||- / -|
Administered by: Other Purchased by: ??
Symptoms: Anaphylactic reaction, Body temperature, Rash
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? Yes, days:
Write-up: Anaphylaxis; body mild rash; This is a spontaneous report from a contactable physician received from the Regulatory Authority. The Regulatory authority report number is v21111935. The patient was a 73-year and 3-month-old female. Body temperature before vaccination was 36.3 degrees Centigrade. The patient had coronary spastic angina, mackerel allergy, and cocoa allergy. On 04Jun2021 at 15:00 (the day of vaccination), the patient received the first dose of BNT162B2 (COMIRNATY, Solution for injection, Lot number EX3617, Expiration date 31Aug2021) via an unspecified route of administration as a single dose for COVID-19 immunization. The course of the event was as follows: The event onset date was reported as 04Jun2021 15:15. On 04Jun2021 at 15:15 (the day of vaccination), 15 minutes after the vaccination, the patient experienced body mild rash. The patient did not have other abnormalities. On 04Jun2021 (the day of vaccination), the outcome of the event was recovered. The reporting physician classified the event as non-serious and assessed that the causality between the event and BNT162B2 as unassessable. The reporting physician commented as follows: Transfer to hospital. This report meets the criteria of Anaphylaxis.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166